Cargando…
Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome
We previously reported that a decrease in butyrate-producing bacteria in the gut is a potential cause of regulatory T cell (Treg) abnormalities in children with idiopathic nephrotic syndrome (INS). Therefore, we hypothesized that administration of butyrate-producing bacteria might reduce INS relapse...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911438/ https://www.ncbi.nlm.nih.gov/pubmed/33530312 http://dx.doi.org/10.3390/nu13020365 |
_version_ | 1783656341792882688 |
---|---|
author | Yamaguchi, Tadashi Tsuji, Shoji Akagawa, Shohei Akagawa, Yuko Kino, Jiro Yamanouchi, Sohsaku Kimata, Takahisa Hashiyada, Masaki Akane, Atsushi Kaneko, Kazunari |
author_facet | Yamaguchi, Tadashi Tsuji, Shoji Akagawa, Shohei Akagawa, Yuko Kino, Jiro Yamanouchi, Sohsaku Kimata, Takahisa Hashiyada, Masaki Akane, Atsushi Kaneko, Kazunari |
author_sort | Yamaguchi, Tadashi |
collection | PubMed |
description | We previously reported that a decrease in butyrate-producing bacteria in the gut is a potential cause of regulatory T cell (Treg) abnormalities in children with idiopathic nephrotic syndrome (INS). Therefore, we hypothesized that administration of butyrate-producing bacteria might reduce INS relapse and the need for immunosuppressants in these patients. Twenty patients in remission from INS (median age 5.3 years, 15 boys) were enrolled in the study and assigned to receive either daily oral treatment with a preparation of 3 g Clostridium butyricum or no probiotic treatment. The number of relapses and requirement for immunosuppressive agents were compared between the two groups. In the probiotic treatment group, analyses of the gut microbiota and Treg measurements were also performed. Probiotic-treated patients experienced fewer INS relapses per year compared with non-probiotic-treated patients (p = 0.016). Further, administration of rituximab in the probiotic treatment group was significantly less frequent compared with the non-probiotic-treated group (p = 0.025). In the probiotic treatment group, analyses before and after probiotic treatment revealed the significant increases in the relative abundance of butyrate-producing bacteria (p = 0.017) and blood Treg counts (p = 0.0065). Thus, oral administration of butyrate-producing bacteria during INS remission may reduce the frequency of relapse and the need for immunosuppressive agents. |
format | Online Article Text |
id | pubmed-7911438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79114382021-02-28 Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome Yamaguchi, Tadashi Tsuji, Shoji Akagawa, Shohei Akagawa, Yuko Kino, Jiro Yamanouchi, Sohsaku Kimata, Takahisa Hashiyada, Masaki Akane, Atsushi Kaneko, Kazunari Nutrients Article We previously reported that a decrease in butyrate-producing bacteria in the gut is a potential cause of regulatory T cell (Treg) abnormalities in children with idiopathic nephrotic syndrome (INS). Therefore, we hypothesized that administration of butyrate-producing bacteria might reduce INS relapse and the need for immunosuppressants in these patients. Twenty patients in remission from INS (median age 5.3 years, 15 boys) were enrolled in the study and assigned to receive either daily oral treatment with a preparation of 3 g Clostridium butyricum or no probiotic treatment. The number of relapses and requirement for immunosuppressive agents were compared between the two groups. In the probiotic treatment group, analyses of the gut microbiota and Treg measurements were also performed. Probiotic-treated patients experienced fewer INS relapses per year compared with non-probiotic-treated patients (p = 0.016). Further, administration of rituximab in the probiotic treatment group was significantly less frequent compared with the non-probiotic-treated group (p = 0.025). In the probiotic treatment group, analyses before and after probiotic treatment revealed the significant increases in the relative abundance of butyrate-producing bacteria (p = 0.017) and blood Treg counts (p = 0.0065). Thus, oral administration of butyrate-producing bacteria during INS remission may reduce the frequency of relapse and the need for immunosuppressive agents. MDPI 2021-01-26 /pmc/articles/PMC7911438/ /pubmed/33530312 http://dx.doi.org/10.3390/nu13020365 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamaguchi, Tadashi Tsuji, Shoji Akagawa, Shohei Akagawa, Yuko Kino, Jiro Yamanouchi, Sohsaku Kimata, Takahisa Hashiyada, Masaki Akane, Atsushi Kaneko, Kazunari Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome |
title | Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome |
title_full | Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome |
title_fullStr | Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome |
title_full_unstemmed | Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome |
title_short | Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome |
title_sort | clinical significance of probiotics for children with idiopathic nephrotic syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911438/ https://www.ncbi.nlm.nih.gov/pubmed/33530312 http://dx.doi.org/10.3390/nu13020365 |
work_keys_str_mv | AT yamaguchitadashi clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT tsujishoji clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT akagawashohei clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT akagawayuko clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT kinojiro clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT yamanouchisohsaku clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT kimatatakahisa clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT hashiyadamasaki clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT akaneatsushi clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome AT kanekokazunari clinicalsignificanceofprobioticsforchildrenwithidiopathicnephroticsyndrome |